Annual report pursuant to Section 13 and 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.19.3.a.u2
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2019
Jan. 31, 2020
Dec. 31, 2019
Oct. 31, 2019
Sep. 30, 2019
Jan. 31, 2019
Oct. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Collaborations                  
Accounts receivable $ 10,111,000   $ 10,111,000         $ 10,111,000 $ 4,077,000
Collaborative arrangement                  
Collaborations                  
Contingent payments               631,700,000  
Specified Development Events | Collaborative arrangement                  
Collaborations                  
Contingent payments               90,500,000  
Specified Regulatory Events | Collaborative arrangement                  
Collaborations                  
Contingent payments               165,200,000  
Specified Product Launch Events | Collaborative arrangement                  
Collaborations                  
Contingent payments               376,000,000  
Grifols                  
Collaborations                  
Upfront payment received           $ 30,000,000      
Deferred revenue 25,300,000   25,300,000         25,300,000  
Revenue, remaining performance obligations 5,000,000   5,000,000         5,000,000  
Grifols | Research and Regulatory Services Performed and License Right                  
Collaborations                  
Revenue recognized               4,700,000  
Grifols | Commercial Milestones                  
Collaborations                  
Contingent payments           297,500,000      
Kissei                  
Collaborations                  
Upfront payment received             $ 33,000,000    
Contingent payments             147,000,000    
Revenue recognized                 $ 30,600,000
Revenue, remaining performance obligations             $ 33,000,000    
Aclaris                  
Collaborations                  
Collaborative payment received         $ 4,000,000        
Revenue recognized               4,000,000  
Accounts receivable 1,500,000   $ 1,500,000         1,500,000  
Celgene                  
Collaborations                  
Collaborative payment received       $ 3,800,000          
Revenue recognized               3,800,000  
fostamatinib | Grifols                  
Collaborations                  
Markup percentage     30.00%            
fostamatinib | Grifols | Terminated agreement upon prior written notice within six months after second anniversary of agreement                  
Collaborations                  
Contingent upfront fee, refund requirement           25,000,000      
fostamatinib | Grifols | Creditable advance royalty payment                  
Collaborations                  
Upfront payment received           2,500,000      
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                  
Collaborations                  
Upfront payment received           $ 17,500,000      
fostamatinib | Grifols | Maximum                  
Collaborations                  
Royalty payment as a percentage of net sales           30.00%      
fostamatinib | Kissei                  
Collaborations                  
Revenue recognized 1,600,000                
Deferred revenue $ 1,400,000   $ 1,400,000         $ 1,400,000  
fostamatinib | Medison Pharma | Financing arrangement                  
Collaborations                  
Upfront payment received       5,000,000          
fostamatinib | Medison Pharma | Commercial and license agreements                  
Collaborations                  
Number of agreements       $ 2          
Subsequent events | fostamatinib | Grifols                  
Collaborations                  
Collaborative payment received   $ 20,000,000              
Subsequent events | fostamatinib | Grifols | Creditable advance royalty payment                  
Collaborations                  
Collaborative payment received   2,500,000              
Subsequent events | fostamatinib | Grifols | EMA approval of fostamatinib                  
Collaborations                  
Collaborative payment received   $ 17,500,000